Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLPT ClearPoint Neuro	$11.89 -1.6%	$12.80	$5.11 ▼ $19.22	$332.79M	1.03	236,071 shs	172,203 shs
LUCD Lucid Diagnostics	$1.59 +19.5%	$1.35	$0.68 ▼ $1.80	$172.02M	1.28	526,715 shs	3.04 million shs
SMLR Semler Scientific	$44.32 -1.4%	$35.99	$21.77 ▼ $81.56	$494.26M	1.33	493,030 shs	1.15 million shs
TMCI Treace Medical Concepts	$5.88 -3.6%	$7.23	$4.54 ▼ $10.79	$369.79M	0.79	607,821 shs	400,460 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLPT ClearPoint Neuro	0.00%	-9.79%	-16.79%	-28.89%	+96.20%
LUCD Lucid Diagnostics	0.00%	+26.19%	+19.55%	+8.90%	+73.77%
SMLR Semler Scientific	0.00%	+8.41%	+28.69%	-7.16%	+89.81%
TMCI Treace Medical Concepts	0.00%	-12.50%	-11.71%	-37.25%	+10.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLPT ClearPoint Neuro	1.6659 of 5 stars	3.5	2.0	2.3	0.0	0.6
LUCD Lucid Diagnostics	3.0427 of 5 stars	3.6	5.0	2.3	1.7	0.6
SMLR Semler Scientific	2.6809 of 5 stars	3.5	1.0	3.1	2.5	1.3
TMCI Treace Medical Concepts	2.2607 of 5 stars	3.1	1.0	2.3	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLPT ClearPoint Neuro	3.00	Buy	$25.00	110.26% Upside
LUCD Lucid Diagnostics	3.20	Buy	$3.50	120.13% Upside
SMLR Semler Scientific	3.00	Buy	$71.00	60.20% Upside
TMCI Treace Medical Concepts	2.29	Hold	$10.16	72.74% Upside

Current Analyst Ratings Breakdown

Latest LUCD, SMLR, TMCI, and CLPT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/15/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
5/14/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
5/9/2025	TMCI Treace Medical Concepts	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $8.60
4/21/2025	LUCD Lucid Diagnostics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.50
4/11/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
4/11/2025	TMCI Treace Medical Concepts	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$9.50 ➝ $8.00
4/1/2025	CLPT ClearPoint Neuro	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$19.00 ➝ $25.00
3/26/2025	LUCD Lucid Diagnostics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$2.00 ➝ $2.00
3/25/2025	LUCD Lucid Diagnostics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$2.00
3/24/2025	LUCD Lucid Diagnostics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$2.50 ➝ $3.00
3/13/2025	TMCI Treace Medical Concepts	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Hold ➝ Hold	$10.00 ➝ $9.50

(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLPT ClearPoint Neuro	$32.24M	10.32	N/A	N/A	$0.86 per share	13.83
LUCD Lucid Diagnostics	$4.17M	41.22	N/A	N/A	($0.47) per share	-3.38
SMLR Semler Scientific	$49.23M	10.04	$2.61 per share	16.95	$10.45 per share	4.24
TMCI Treace Medical Concepts	$210.82M	1.75	N/A	N/A	$2.24 per share	2.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLPT ClearPoint Neuro	-$22.09M	-$0.76	N/A	N/A	N/A	-59.64%	-62.10%	-38.39%	8/6/2025 (Estimated)
LUCD Lucid Diagnostics	-$52.67M	-$1.34	N/A	N/A	N/A	-1,069.87%	N/A	-123.54%	8/11/2025 (Estimated)
SMLR Semler Scientific	$20.58M	-$2.61	9.03	∞	N/A	72.65%	50.77%	47.04%	8/4/2025 (Estimated)
TMCI Treace Medical Concepts	-$49.53M	-$0.85	N/A	N/A	N/A	-30.33%	-51.12%	-26.36%	8/5/2025 (Estimated)

Latest LUCD, SMLR, TMCI, and CLPT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CLPT ClearPoint Neuro	-$0.15	-$0.22	-$0.07	-$0.22	$8.21 million	$8.49 million
5/13/2025	Q1 2025	SMLR Semler Scientific	N/A	-$0.76	N/A	-$6.74	N/A	$8.84 million
5/8/2025	Q1 2025	TMCI Treace Medical Concepts	-$0.31	-$0.25	+$0.06	-$0.25	$52.07 million	$52.57 million
2/26/2025	Q4 2024	CLPT ClearPoint Neuro	-$0.15	-$0.20	-$0.05	-$0.20	$8.23 million	$7.77 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLPT ClearPoint Neuro	N/A	N/A	N/A	N/A	N/A
LUCD Lucid Diagnostics	N/A	N/A	N/A	N/A	N/A
SMLR Semler Scientific	N/A	N/A	N/A	N/A	N/A
TMCI Treace Medical Concepts	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLPT ClearPoint Neuro	N/A	4.54	3.61
LUCD Lucid Diagnostics	N/A	1.18	1.14
SMLR Semler Scientific	N/A	3.14	3.09
TMCI Treace Medical Concepts	0.51	4.12	2.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLPT ClearPoint Neuro	30.08%
LUCD Lucid Diagnostics	74.01%
SMLR Semler Scientific	49.37%
TMCI Treace Medical Concepts	84.08%

Insider Ownership

Company	Insider Ownership
CLPT ClearPoint Neuro	6.97%
LUCD Lucid Diagnostics	6.80%
SMLR Semler Scientific	30.20%
TMCI Treace Medical Concepts	27.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLPT ClearPoint Neuro	110	27.99 million	25.90 million	Optionable
LUCD Lucid Diagnostics	70	108.19 million	54.12 million	No Data
SMLR Semler Scientific	120	11.15 million	6.47 million	Not Optionable
TMCI Treace Medical Concepts	250	62.89 million	47.08 million	Optionable

LUCD, SMLR, TMCI, and CLPT Headlines

Recent News About These Companies

Lost Money on Treace Medical Concepts, Inc. (TMCI)? Urged to Join Class Action Before June 10, 2025 - Contact Levi & Korsinsky

May 25 at 10:00 AM | accessnewswire.com

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – TMCI

May 25 at 9:17 AM | globenewswire.com

Class Action Lawsuit Filed Against Treace Medical Concepts, Inc. (TMCI) - Recover Losses - Contact Levi & Korsinsky Before June 10, 2025

May 25 at 8:47 AM | accessnewswire.com

Class Action Alert: Levi & Korsinsky Reminds Treace Medical Concepts, Inc. (TMCI) Investors of June 10, 2025 Deadline

May 25 at 7:13 AM | accessnewswire.com

TMCI SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Treace Medical Concepts, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

May 25 at 7:00 AM | accessnewswire.com

Jane Street Group LLC Sells 158,845 Shares of Treace Medical Concepts, Inc. (NASDAQ:TMCI)

May 25 at 3:08 AM | marketbeat.com

Class Action Lawsuit Alert: Levi & Korsinsky Reminds Treace Medical Concepts, Inc. (TMCI) Investors of June 10, 2025 Deadline

May 24 at 6:01 PM | accessnewswire.com

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TMCI

May 24 at 5:00 PM | accessnewswire.com

TMCI Investors Have Opportunity to Lead Treace Medical Concepts, Inc. Securities Fraud Lawsuit

May 24 at 3:49 PM | gurufocus.com

TMCI Investors Have Opportunity to Lead Treace Medical Concepts, Inc. Securities Fraud Lawsuit

May 24 at 2:21 PM | prnewswire.com

Point72 Asset Management L.P. Invests $1.41 Million in Treace Medical Concepts, Inc. (NASDAQ:TMCI)

May 24 at 4:14 AM | marketbeat.com

TMCI LAWSUIT ALERT: Levi & Korsinsky Notifies Treace Medical Concepts, Inc. Investors – Lead Plaintiff Deadline June 10, 2025

May 23 at 6:30 PM | accessnewswire.com

TMCI Investors with Large Losses Should Contact Robbins LLP for Information About the Treace Medical Concepts, Inc. Class Action Lawsuit

May 23 at 6:09 PM | globenewswire.com

Class Action Alert: Levi & Korsinsky Reminds Treace Medical Concepts, Inc. (TMCI) Investors of June 10, 2025 Deadline

May 23 at 5:15 PM | accessnewswire.com

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TMCI

May 23 at 5:00 PM | accessnewswire.com

Investors in Treace Medical Concepts, Inc. (TMCI): Protect Your Rights - Contact Levi & Korsinsky Before June 10, 2025

May 23 at 1:15 PM | accessnewswire.com

Investor Alert: Deadline Approaching to Join Treace Medical Concepts, Inc. (TMCI) Class Action - Contact Levi & Korsinsky

May 23 at 12:15 PM | accessnewswire.com

Treace Medical Concepts, Inc. (TMCI) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit

May 23 at 12:00 PM | prnewswire.com

Securities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) Investors - Contact Levi & Korsinsky Before June 10, 2025

May 23 at 11:06 AM | accessnewswire.com

TMCI Investors Have the Opportunity to Lead the Treace Medical Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

May 23 at 10:20 AM | globenewswire.com

Class Action Lawsuit Alert: Levi & Korsinsky Reminds Treace Medical Concepts, Inc. (TMCI) Investors of June 10, 2025 Deadline

May 23 at 7:15 AM | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LUCD, SMLR, TMCI, and CLPT Company Descriptions

ClearPoint Neuro NASDAQ:CLPT

$11.89 -0.19 (-1.57%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$11.90 +0.01 (+0.08%)

As of 05/23/2025 07:43 PM Eastern

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

Lucid Diagnostics NASDAQ:LUCD

$1.59 +0.26 (+19.55%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$1.64 +0.04 (+2.83%)

As of 05/23/2025 07:58 PM Eastern

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Semler Scientific NASDAQ:SMLR

$44.32 -0.61 (-1.36%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$43.92 -0.40 (-0.89%)

As of 05/23/2025 07:59 PM Eastern

Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.

Treace Medical Concepts NASDAQ:TMCI

$5.88 -0.22 (-3.61%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$5.88 0.00 (0.00%)

As of 05/23/2025 04:46 PM Eastern

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time